-
Mashup Score: 0Real-World Use of Tafasitamab Supports Clinical Benefit in Relapsed, Refractory DLBCL | Blood Cancers Today - 4 month(s) ago
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Twin-Agent Therapy Evaluated for Philadelphia Chromosome-Positive ALL, CML in Lymphoid Blast Phase | Blood Cancers Today - 4 month(s) ago
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
🔬 Researchers from @MoffittNews have evaluated blinatumomab plus ponatinib combination therapy for Ph+ ALL and #CML in lymphoid blast phase. 📖 Read here: https://t.co/niWYPfBVcd https://t.co/E6SpV3iwbx
-
-
Mashup Score: 1Highlights in Myeloma Research from ASH 2024 With Dr. Rakesh Popat | Blood Cancers Today - 4 month(s) ago
Dr. Rakesh Popat joins the hosts of “Blood Cancer Talks” to highlight myeloma research presented at ASH 2024, such as the AQUILA and CARTITUDE-4 trials.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
Happy Saturday! This weekend, check out the latest episode of @BloodCancerTalk with @DrRakeshPopat (@uclh) on #myeloma updates from #ASH2024, including the iMMagine-1 and CARTITUDE-4 trials. 🎧 Listen here: https://t.co/3UAPmvbeYa @rajshekharucms @AshKishtagari @Eddie_Cliff https://t.co/uul65r7Ax4
-
-
Mashup Score: 1Brentuximab Vedotin Combination Reduces Risk of Death by 37% in Relapsed or Refractory DLBCL | Blood Cancers Today - 4 month(s) ago
The addition of brentuximab vedotin to lenalidomide plus rituximab resulted in a statistically significant OS advantage over R2 alone in patients with relapsed or refractory DLBCL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Adding brentuximab vedotin to lenalidomide + rituximab resulted in a statistically significant overall survival advantage over rituximab alone in patients with relapsed/refractory #DLBCL, according to a study led by @nancybartlettMD of @SitemanCenter. 📰 https://t.co/34poVYyw0J https://t.co/LLKw07pPKi
-
-
Mashup Score: 2Better CAR T-Cell Outcomes Shown in Transformed Follicular Lymphoma Versus DLBCL | Blood Cancers Today - 4 month(s) ago
Patients with transformed follicular lymphoma (tFL) showed a distinct survival advantage compared with patients with dnDLBCL after CAR T-cell therapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Patients with transformed follicular #lymphoma showed a distinct survival advantage compared with patients with de novo #DLBCL after receiving CAR T-cell therapy, according to a study led by @Matt_Cortese of @RoswellPark. 📰 Read more: https://t.co/TFviUTpYGp https://t.co/YzIylc9Iln
-
-
Mashup Score: 2
Three experts discuss the past year in advances in MDS care and newly-presented ad hoc analysis on quality of life from the COMMANDS trial.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Jamile Shammo (@NUFeinbergMed) hosted an #MDS expert panel with @AYACOUB7 (@KUMedCenter), @tiffytanaka (@UCSDHealth) and @PratzKW (@PennCancer) at #ASH24! In the first segment, they discuss advances in MDS care and QoL data from the COMMANDS trial. 📺 https://t.co/mZoc1q3YDb https://t.co/1vloQNHH93
-
-
Mashup Score: 0New Trial to Test Novel Combination in Relapsed, Refractory MCL | Blood Cancers Today - 4 month(s) ago
Researchers are launching a new clinical trial that will evaluate the combination of the bispecific antibody glofitamab with the noncovalent BTK inhibitor pirtobrutinib in MCL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📝 A new clinical trial will evaluate the combination of glofitamab with pirtobrutinib in patients with relapsed or refractory #MCL who are BTK inhibitor naive or intolerant. @MRSeshadri, of @UCSF, presented the study's design at #ASH24. 💡 Learn more: https://t.co/l9cY4NI82R https://t.co/r52H1ZM3yz
-
-
Mashup Score: 4Get to Know ... Craig Cole, MD | Blood Cancers Today - 4 month(s) ago
Dr. Cole spoke about the family tragedies that made him an oncologist, his commitment to mitigating disparities for Black patients with myeloma, and more.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🙌 Get to Know...Craig Cole, MD, of @karmanoscancer! 💬 Dr. Cole spoke about the family tragedies that made him an oncologist, his commitment to mitigating disparities for Black patients with #myeloma, and more. 📚 Read here! https://t.co/vQoV50EUKz https://t.co/LpDB5JLgIM
-
-
Mashup Score: 1ASC4FIRST Trial: Asciminib Shows Favorable Safety, Efficacy Versus Investigator-Selected TKIs in CML | Blood Cancers Today - 4 month(s) ago
Asciminib showed superior safety and efficacy compared with standard-of-care, second-generation, investigator-selected TKIs in patients with newly diagnosed chronic phase CML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
☑️ Asciminib showed superior safety and efficacy compared with standard-of-care, second-generation, investigator-selected TKIs in newly diagnosed chronic phase #CML, according to the phase III ASC4FIRST study led by @GCC_Cortes of @GACancerCenter. 📚 https://t.co/A5YrL5X65V https://t.co/6y8SOjCmyv
-
-
Mashup Score: 5More Is More: Quadruplets Gain a Foothold as Standard in Newly Diagnosed MM | Blood Cancers Today - 4 month(s) ago
Blood Cancers Today recently spoke with several clinicians about how quadruplet therapy is changing the myeloma treatment landscape.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Our latest feature is out now! 🎉 We spoke with @nishjo76 (@WinshipAtEmory), @DoctorAKrishnan, (@cityofhopeoc), and @TMSchmidtMD (@UWCarbone) on how quadruplet therapy is changing the #myeloma treatment landscape. 📰 Read here: https://t.co/JFO6aOVFOm https://t.co/z2I9kFbssY
-
A recent study of the real-world effectiveness of tafasitamab for relapsed or refractory #DLBCL supported the findings of clinical benefit of the drug in this patient population. The study was presented by Kimberly Saverno, PhD, of @Incyte, at #ASH24. ➡️ https://t.co/rttI4hXMaD https://t.co/J1xy0rYHlF